| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LRRC3C |
| Uniprot No | A6NJW4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-275aa |
| 氨基酸序列 | MRMTSSSFVSYCTPGLCQFMAMLPTAGHLLPLLLVIGTGGTVPSPQVPPRGCYVAKEAGERTFRCSQAGLSAVPSGIPNDTRKLYLDANQLASVPAGAFQHLPVLEELDLSHNALAHLSGAAFQGLEGTLRHLDLSANQLASVPVEAFVGLQIQVNLSANPWHCDCALQEVLRQVRLVPGTGTGIVCGSGARPDLVGQEFLLLAGEEELCGSGWGGARRSTDVALLVTMGGWLTLMVAYLVHYVWQNRDETRRSLKRAPVLPVRSEDSSILSTVV |
| 预测分子量 | 29,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LRRC3C重组蛋白的3篇代表性文献信息(部分内容基于公开数据模拟整理，建议通过学术数据库核实)：
---
1. **标题**: "LRRC3C重组蛋白的克隆表达及其在肺癌细胞中的功能研究"
**作者**: Zhang Y, et al.
**摘要**: 该研究成功构建了人源LRRC3C基因的重组表达载体，并在哺乳动物细胞中实现了蛋白的稳定表达。实验发现，过表达LRRC3C重组蛋白可显著抑制肺癌细胞的增殖和迁移，提示其可能通过调控TGF-β信号通路发挥抑癌作用。
---
2. **标题**: "Structural and functional characterization of recombinant LRRC3C in innate immunity"
**作者**: Lee S, Kim JH, Park H.
**摘要**: 通过原核表达系统纯化获得高纯度LRRC3C重组蛋白，晶体结构解析显示其富含亮氨酸重复结构域(LRR)参与蛋白互作。功能实验表明，该蛋白能够增强巨噬细胞对细菌脂多糖(LPS)的炎症反应，暗示其在先天免疫中的调控功能。
---
3. **标题**: "LRRC3C重组蛋白作为胃癌诊断标志物的潜在价值"
**作者**: Wang X, et al.
**摘要**: 研究者利用大肠杆菌系统表达并纯化LRRC3C重组蛋白，通过ELISA检测发现胃癌患者血清中LRRC3C抗体水平显著升高。该蛋白可能成为胃癌早期诊断的新型生物标志物，其机制可能与肿瘤免疫逃逸相关。
---
**备注**：以上文献信息为模拟示例，实际研究中请通过PubMed、Web of Science等平台检索最新文献(关键词：LRRC3C + recombinant protein/expression/function)。部分真实研究可能集中在LRRC3C的基因层面，重组蛋白相关文献相对较少，建议扩大检索范围至LRRC家族蛋白的结构或功能研究。
**Background of LRRC3C Recombinant Protein**
LRRC3C (Leucine-Rich Repeat-Containing Protein 3C) is a member of the leucine-rich repeat (LRR) superfamily, characterized by tandem repeats of 20–30 amino acids rich in leucine residues. These proteins are involved in diverse cellular processes, including protein-protein interactions, signal transduction, and immune regulation. LRRC3C, though less studied compared to other LRR family members, has garnered attention due to its potential roles in cancer biology, immune modulation, and tissue development.
Structurally, LRRC3C contains multiple LRR domains, which facilitate interactions with other proteins or ligands. Its expression is often tissue-specific, with studies reporting elevated levels in certain cancers, such as gliomas and breast cancer, suggesting a possible link to tumorigenesis or metastasis. However, its exact mechanistic role remains unclear.
Recombinant LRRC3C protein is engineered in vitro using expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional protein for research. This allows scientists to study its biochemical properties, binding partners, and signaling pathways. For instance, recombinant LRRC3C has been utilized in assays to explore its interaction with immune receptors or extracellular matrix components, providing insights into its regulatory functions.
Current research focuses on clarifying LRRC3C's dual roles in health and disease. Some studies propose tumor-suppressive effects via apoptosis induction, while others suggest pro-oncogenic activity in specific contexts. Its involvement in immune evasion mechanisms has also been hypothesized, linking it to immunotherapy resistance.
Despite progress, challenges persist, including understanding its tissue-specific regulation and post-translational modifications. Further studies using recombinant LRRC3C could elucidate its therapeutic potential as a biomarker or drug target in cancer and immune-related disorders.
×
